Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $9 | $8 | $8 | $7 |
| % Growth | 6% | 4.9% | 6.8% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $8 | $7 | $7 | $6 |
| % Margin | 91.6% | 89.1% | 88.4% | 85.9% |
| R&D Expenses | $16 | $21 | $24 | $26 |
| G&A Expenses | $0 | $14 | $0 | $16 |
| SG&A Expenses | $13 | $17 | $19 | $15 |
| Sales & Mktg Exp. | $0 | $3 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $29 | $38 | $43 | $42 |
| Operating Income | -$21 | -$32 | -$36 | -$35 |
| % Margin | -246.8% | -400.1% | -466.5% | -492.9% |
| Other Income/Exp. Net | -$3 | -$4 | -$3 | -$6 |
| Pre-Tax Income | -$24 | -$36 | -$39 | -$42 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$36 | -$39 | -$42 |
| % Margin | -283.6% | -444.7% | -503.6% | -580.9% |
| EPS | -0.42 | -0.63 | -0.68 | -0.74 |
| % Growth | 33.3% | 7.4% | 8.1% | – |
| EPS Diluted | -0.42 | -0.63 | -0.68 | -0.74 |
| Weighted Avg Shares Out | 57 | 57 | 57 | 57 |
| Weighted Avg Shares Out Dil | 57 | 57 | 57 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $4 | $5 | $4 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$21 | -$31 | -$34 | -$37 |
| % Margin | -246.8% | -385.7% | -445.3% | -519.4% |